Vaxcyte, Inc. filed a Form 8-K with the SEC on September 3, 2026, disclosing the appointment of David McAvoy as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary, effective August 31, 2026.

Key Highlights

  • New appointment: David McAvoy was named Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary of Vaxcyte, Inc., effective August 31, 2026.
  • Existing role continues: Mikhail Eydelman continues to serve as Senior Vice President, General Counsel, according to the filing.
  • Press release issued: On September 3, 2026, the company issued a press release titled "Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data."
  • Guidance update referenced: The press release also referenced a narrowing of guidance for expected VAX-31 OPUS-1 topline data, furnished as Exhibit 99.1.
  • Filing signed by: Andrew Guggenhime, President and Chief Financial Officer, signed the report on September 3, 2026.

Vaxcyte Expands Legal Leadership With McAvoy Appointment

According to the Form 8-K filed by Vaxcyte, Inc. (NASDAQ:PCVX) on September 3, 2026, the company appointed David McAvoy as its Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary, with the appointment taking effect August 31, 2026. The filing indicates that Mikhail Eydelman will continue in his role as Senior Vice President, General Counsel alongside McAvoy's new positions.

The filing also disclosed, under Item 7.01 (Regulation FD), that the company issued a press release on September 3, 2026, covering both the legal leadership changes and a narrowing of guidance for expected VAX-31 OPUS-1 topline data. The press release was furnished as Exhibit 99.1 and incorporated by reference. The company noted that the information in Item 7.01 and Exhibit 99.1 "shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934" and is not subject to the liabilities of that section unless expressly incorporated by reference in another filing.

The 8-K was signed by Andrew Guggenhime in his capacity as President and Chief Financial Officer. Vaxcyte is a Delaware-incorporated company headquartered at 825 Industrial Road, Suite 300, San Carlos, California 94070.

What Was Disclosed

Vaxcyte's 8-K reported the appointment of David McAvoy as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary effective August 31, 2026, while Mikhail Eydelman remains Senior Vice President, General Counsel. A related press release, also referencing VAX-31 guidance, was furnished as an exhibit.